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www.jacctctabstracts2014.com SATURDAY, SEPTEMBER 13, 2014, 5:00 PM–7:00 PMstage kidney disease on the affected diseased kidney. One patient was pre-renal
transplant and had both kidneys treated. One week after cystoscopy aided transurethral
treatment with the NephroBlate device, the previously planned nephrectomy was
performed. Following this we treated 4 resistant hypertensive patients.
Results: Nephrectomy Patients – Procedure time was between 9 to 15 min., and no
adverse effects were recorded. The histopathological results of the treated kidney in all
cases showed a signiﬁcant destruction of the peri-pelvic nerves from the renal pelvic
space to the serosa (1.75mm). We then proceeded with our clinical studies on resistant
hypertensive patients. Resistant Hypertensive Patients – Four patients were treated
utilizing a standard urologic procedure with OR times of 16-25 min. Within 30 seconds
of treatment of the ﬁrst kidney, a blood pressure response was noted (reduction of mean
systolic blood pressure 44mmHg, reduction ofmean diastolic blood pressure 13mmHg).
Following the procedure, none of the patients had signiﬁcant pain or bleeding.
Conclusions: At six month follow-up, the patients continue to be normotensive with
no renal issues. The blood pressure response was immediate and occurred while the
patients were under general anesthesia. In this small series of humans treated with
limited follow-up, we see a promising nonvascular alternative for renal denervation
for treatment for resistant.
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Background: Catheter-based renal denervation (RDN) has demonstrated efﬁcacy in
controlling blood pressure in clinical trials. The long-term effect in blood pressure and
nerve “regrowth” has been questioned. We aimed to study and characterize the renal
nerve response following RDN acutely and long term.
Methods: Swine underwent bilateral RDN and they were followed for 7, 30, 90 and
180 days. At each time point renal arteries were harvested for further histological
analysis. A representative section of each time point was selected for regular H&E
staining and immunohistochemical (IHC) analysis. The IHC evaluation of the renal
arteries consisted on S100 (Schwann cell), Tyrosine hydroxylase (TH; efferent motor
renal nerves), calcitonin gene-related peptide (CGRP) and substance P (SP); (CGRP
and SP afferent sensory renal nerves) to provide a complete characterization of the
nerve response to treatment over time.
Results: H&E stain displayed a nerve injury in acute (7 days: nerve necrosis, distal
atrophy) and chronic follow up (180 days: nerve ﬁbrosis). At the longer time points
H&E displayed nerve remodeling and tentative regeneration. At chronic time points
there was morphological recovery of S100, TH, CGRP and SP. However, there was
evidence of TH and S100 staining and extension of neural bundles within and across
the thickened perineurium, forming neuroﬁbrous tangles (perineural neuromatous
regeneration, PNR). IHC revealed TH and S100 positive ﬁbers within and beyond the
ﬁbrous perineurium as early as 7 days post-RDN. This PNR becomes more evident at
longer time points. At 180 days, these neuromatous tangles became very prominent to
the point of being evident with HE where affected nerves were sometimes completely
remodeled into neuromatous proliferative bundles.
Conclusions: Nerves regeneration has been demonstrated in renal transplant models.
Long term follow up has demonstrated nerve count increase following RDN in pre-
clinical studies. We demonstrate that this “regenerative nerve attempt” occurs as early
as 7 days post-RDN resulting in a poorly organized tangles of nerve ﬁbers and con-
nective tissue. This is the ﬁrst complete histological characterization of neuromatous




Non-invasive Renal Denervation Using Externally Delivered Focused
Ultrasound: Early Experience Using Doppler based Imaging Tracking and
Targeting for Treatment
John A. Ormiston1, Thomas Anderson2, Todd J. Brinton3, Omar Dawood2,
Michael Gertner2, Patrick Kay4, Petr Neuzil5, Zdenek Starek6
1Professor, University of Auckland Medical School, Auckland, New Zealand, 2Kona
Medical, Bellevue, WA, 3Stanford University, Palo Alto, CA, 4Middlemore and
Auckland Hospitals, Auckland, New Zealand, 5Nemocnice na Homolce, Prague,
Czech Republic, 6St. Anne’s University Hospital, Brno, Czech Republic
Background: The Kona Medical Surround Sound System is a noninvasive treat-
ment for renal denervation and delivers externally focused ultrasound to the renal
nerves using Doppler based ultrasound image guidance to track and correct for renal
artery motion during treatment.
Methods: Twenty-three patients with severe treatment resistant hypertension, deﬁned
as persistent systolic blood pressure (SBP) greater than 160 mmHg despite three or
more antihypertensive medications, were treated non-invasively with the Kona
Medical Surround Sound System to evaluate the safety and feasibility of a novel
approach to this treatment for renal denervation. Focused ultrasound energy was
delivered to the proximal renal arteries and surrounding tissue using non-invasiveJACC Vol 64/11/Suppl B j September 13–17, 2014 j TCT Abstracts/HyDoppler-based imaging and continuous tracking with automatic correction for kidney
motion throughout treatment. All patients received conscious sedation during treat-
ment and tolerated treatment well.
Results: Fourteen patients completed at least the 6-Week Follow-up Visit, and three
subjects completed the 24-Week Follow-up Visit. No serious device related events
have been reported during treatment or during the initial three week follow-up period.
Six patients reported mild, clinically insigniﬁcant back pain immediately following
treatment with complete resolution within 24 hours in a majority of patients. One
patient developed post-procedural transient hypokalemia, probably unrelated to renal
denervation, which resolved with potassium replacement. Of the 14 patients who have
completed 6-Week Follow-up Visits, 11 (78.6%) achieved a systolic blood pressure
(SBP) decrease of at least 10 mmHg, with an average SBP decrease of 23 mmHg and
an average diastolic blood pressure decrease of 9 mmHg.
Conclusions: Initial results of this fully non-invasive renal denervation system
demonstrated it was well tolerated and safely delivered in 23 patients. Doppler-based
image guidance for targeting and continuous tracking with automatic motion
correction enabled patients to beneﬁt from renal denervation therapy without the
invasive risks associated with catheter based renal denervation.
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Background: The Paradise Renal Denervation System (ReCor Medical, Palo Alto,
CA) is designed to deliver ultrasound (US) energy to perform circumferential
denervation of the renal sympathetic nerves. As current renal denervation systems do
not allow for immediate biofeedback to the user regarding effective denervation, it is
critical to generate mechanism of action data. We demonstrate in a preclinical model
and in humans that US denervation decreases sympathetic nerve activity post pro-
cedure, which should to translate into potential clinical beneﬁt in humans.
Methods: Bilateral ultrasound renal denervation was performed in 8 normotensive
pigs. Pigs received 1, 2, or 3 bilateral US emissions. At 7 days, kidney norepinephrine
(NEPI) levels were measured by HPLC/MS to assess sympathetic nerve activity, and
renal nerve injury was assessed histologically. MSNA data was collected at baseline
and one month post procedure in 5 patients enrolled in the REALISE trial in France.
Patients received 2 or 3 bilateral US emissions. Ofﬁce BP was recorded at 1 month
and correlations between BP and MSNA reduction performed.
Results: Kidney NEPI levels were signiﬁcantly reduced in all animals and correlated
with the degree of nerve damage. 2 or 3 bilateral ultrasound emissions resulted in 89%
or 97% NEPI reduction, respectively. A reduction in NEPI 89% correlated with
ablation of 76% of nerves along the length of the renal artery. In humans, a reduction
in MSNA was observed in all 5 patients (mean 17%) 1 month following US dener-
vation. The decrease in MSNA correlated with a decrease in BP 10mmHg in 4 of
5 patients suggesting that US is effective in reducing sympathetic nerve activity,
which may translate into clinical beneﬁt in a subset of patients.
Conclusions: Translational data is critical towards understanding the mechanism of
action associated with renal denervation devices. Ultrasound renal denervation
effectively and consistently reduced sympathetic activity acutely in a preclinical
model and in a small subset of patients providing evidence that the technology is
performing as intended in vivo.
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Background: Catheter-based renal denervation (RDN) causes signiﬁcant blood
pressure (BP) reductions in patients with resistant hypertension. The purpose of this
study was to identify predictors of BP response.
Methods: This is a single-center, non-randomized, uncontrolled retrospective analysis
of hypertensive patients. One hundred one consecutive patients with resistant hyper-
tension who underwent RDN with the Symplicity catheter were included. Uni- and
multivariate logistic regression analyses were performed to detect baseline predictors
of a signiﬁcant BP response 6 months after RDN (age, gender, ofﬁce and ambulatory
BP, renal function, body mass index [BMI], diabetes mellitus, antihypertensive
medication, number of ablations). Primary endpoint was the change in average ofﬁce
BP at 6-month follow-up compared to baseline and between groups.
Results: The patients included in this study were 61 males and 40 females, with a
median age of 62.8  11.0 years. The procedure was technically uneventful in all
patients. Mean BP at baseline was 166.6/90.2  22.5/16.4 mmHg and decreased by
-14.7 (p< 0.0001) /-5.3 (p< 0.001)  22.8/14.1 mmHg at 6-month follow-up.
Similarly, paired analysis of 24 hour-ambulatory blood pressure measurement (n¼71)
showed a signiﬁcant reduction of mean systolic BP by 6.8  14.4 mmHg (p< 0.0002).pertension Therapies Including Renal Denervation B121
SATURDAY, SEPTEMBER 13, 2014, 5:00 PM–7:00 PM www.jacctctabstracts2014.comUpon univariate analyses, baseline ofﬁce systolic BP (p< 0.0001) and BMI (p¼0.014)
were identiﬁed as signiﬁcant predictors of a BP response after 6 months. Obese pa-
tients with a BMI of 30.0 had a signiﬁcantly lower BP response after 6 months
(-8.9  18.8 mmHg) compared to normal-weight patients with a BMI  29.9 (-20.1 
24.9 mmHg; p¼0.013). Importantly, stepwise backward regression model revealed
baseline ofﬁce systolic BP (standardized ß¼-0.46; r¼-0.47; p< 0.0001) and BMI
(standardized ß¼0.21; r¼0.95; p¼0.019) as signiﬁcant variables for BP response after
6 months. The other variables remained insigniﬁcant.
Conclusions: Hypertension severity and BMI are important predictors of BP response
to RDN. BP reduction after RDN is, in fact, more pronounced in patients with lower
BMIs. These ﬁndings may help in patient selection.
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Background: Percutaenous renal artery denervation has been shown to decrease
blood pressure among patients with resistant arterial hypertension. We present in this
review a meta-analysis of all randomized controlled trials evaluating effectiveness and
complications of catheter-based RDN for blood pressure control in patients with
resistant hypertension.
Methods: Pub Med, Chocrane and Scopus were systematically searched up to May
2014. Primary outcomes were 6 months reduction of ofﬁce systolic and diastolic blood
pressure. Secondary outcomes were 24 hours systolic blood pressure reduction, more
than 10mmHg systolic blood pressure reduction and MACE (death, stroke/TIA, and
AMI). We used Fixed or Random Effect analysis using the Cochrane Handbook of
Systematic Reviews.
Results: 3 RCTs provided a total of 651 patients; 415 inthe RDN groupd and 236 in
the control. Ofﬁce systolic blood pressure decrease of 18.29 mmHg and 6.83 mmHg
mean diastolic reduction(for both p < 0.05). A strong trend in the 24-hours systolic
blood pressure mean reduction -10.99 at 6 months and signiﬁcantly more patients
responded to the RDN therapy presenting with  10 mmHg systolic blood pressure
decrease (for both p ¼0.05) without any MACE.Conclusions: Resistant hypertension treated with catheter-based RDN respond
better to blood pressure reduction and with sustained control without carrying
signiﬁcant kidney and cardiovascular complications. It is yet to be determined if
some RDN catheters are capable to provide more concise results and therefore lead
to better procedural outcomes. Therefore more randomized clinical data are
warranted.B122 JACC Vol 64/11/Suppl B j September 13–17, 2014TCT-416
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Background: Renal denervation interrupts the sympathetic pathways to the kidneys
and therefore may decrease blood pressure. This technique is increasingly being
evaluated for the management of resistant hypertension.
Methods: All the available electronic databases were queried for studies on renal
denervation for resistant hypertension. Studies that had a minimum follow up period
of 6 months were included. Meta-analysis of the weighted mean difference of pre and
post renal denervation blood pressures was performed using random effects model.
Results: A total of 18 studies met our inclusion and exclusion criteria and were
included in the ﬁnal analysis. Ofﬁce blood pressures were reported in 16 studies, while
ambulatory blood pressures were reported in 7 studies. At 6 months, post renal
denervation, the ofﬁce systolic blood pressure decreased by 25.2 mm Hg (95% CI,
24.7 – 25.7 mm Hg). Ofﬁce diastolic blood pressure was lowered by 9.6 mm Hg (95%
CI, 8.1 – 11 mm Hg). The ambulatory systolic and diastolic blood pressures also
decreased by 12 mm Hg (95% CI, 4.4 – 19.7 mm Hg) and 6.5 mm Hg (95% CI, 3.3 –
9.5 mm Hg), respectively. At 1 year after renal denervation, the ofﬁce systolic blood
pressure was lowered by 24.6 mm Hg (95% CI, 21.9 – 27.4 mm Hg). The ofﬁce
diastolic blood pressure was decreased by 10.7 mm Hg (95% CI, 8.4 – 12.9 mm Hg) at
1 year follow up.Conclusions: Renal denervation effectively lowers both systolic and diastolic blood
pressures in subjects with resistant hypertension. The blood pressure lowering effect
appeared to be sustained at 1 year after renal denervation.
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Background: The Paradise Renal Denervation System (ReCor Medical, Palo Alto,
CA) delivers ultrasound (US) energy to perform circumferential denervation of the
renal sympathetic nerves. The REALISE trial is a French post-market study in
moderate resistant hypertensive (RH) patients with active hypertension medication
management. Six-month safety and effectiveness data will be presented, as will
MSNA data collected in a subset of patients to evaluate the ability of US denervation
to down-regulate sympathetic activity.
Methods: The REALISE trial is a prospective, single-arm, open-label study. The
study enrolled patients with ofﬁce BP >140/90, conﬁrmed by ambulatory measures,
and on a minimum of 3 medications. Patients were treated with up to 3 US emissions
bilaterally. All patients underwent CT-scan or MRI at baseline and follow-up to assess
the renal arteries. Ofﬁce and ambulatory BP measures and changes in medications
were recorded at regular intervals. MSNA was obtained in ﬁve patients at baseline and
post procedure.j TCT Abstracts/Hypertension Therapies Including Renal Denervation
